Central Reduction of Food Noise and Cravings: The hypothalamic and mesolimbic GLP-1 receptor activity that semaglutide produces reduces the subjective preoccupation with food, cravings, and reward-driven eating that behavioral approaches alone struggle to override
However, the length of time it takes to see results from GLP-1 medication will vary from person to person
38 Because of the unique absorption characteristics of oral semaglutide, it is important to consider how other commonly used drugs may be affected when given concomitantly with the oral GLP-1 receptor agonist
Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, et al
When compounding in compliance with federal and state law, compounded drugs are not subject to FDA approval and are not evaluated for safety or efficacy